公开(公告)号：US08741314B2

公开(公告)日：2014-06-03

申请号：US13738698

申请日：2013-01-10

申请人： Sanofi Pasteur Inc.

发明人： Robert P. Ryall

IPC分类号： A61K39/095 ,  A61K39/385 ,  A61K39/02 ,  A61K39/00 ,  A01N43/04 ,  C07H1/00 ,  A61K39/116

CPC分类号： A61K47/64 ,  A61K39/095 ,  A61K39/116 ,  A61K39/39 ,  A61K47/02 ,  A61K47/08 ,  A61K47/24 ,  A61K47/61 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70

摘要： The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.

公开(公告)号：US09844601B2

公开(公告)日：2017-12-19

申请号：US14855994

申请日：2015-09-16

申请人： Sanofi Pasteur Inc.

发明人： Robert P. Ryall

IPC分类号： A61K39/095 ,  A61K47/48 ,  A61K47/08 ,  A61K47/02 ,  A61K39/39 ,  A61K39/116 ,  A61K47/24 ,  A61K47/61 ,  A61K47/64 ,  A61K39/00

CPC分类号： A61K47/64 ,  A61K39/095 ,  A61K39/116 ,  A61K39/39 ,  A61K47/02 ,  A61K47/08 ,  A61K47/24 ,  A61K47/61 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70

摘要： The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.

公开(公告)号：US20150174259A1

公开(公告)日：2015-06-25

申请号：US14636870

申请日：2015-03-03

申请人： Sanofi Pasteur Inc.

发明人： Robert P. Ryall

IPC分类号： A61K47/48 ,  A61K39/39 ,  A61K47/24 ,  A61K39/095

CPC分类号： A61K47/64 ,  A61K39/095 ,  A61K39/116 ,  A61K39/39 ,  A61K47/02 ,  A61K47/08 ,  A61K47/24 ,  A61K47/61 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70

摘要： The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.

摘要翻译： 本发明描述了一种联合疫苗，其提供针对脑膜炎球菌引起的脑膜炎球菌疾病的广泛保护。 疫苗由四种不同的多糖 - 蛋白质缀合物组成，其被配制成单一剂量的疫苗。 来自脑膜炎奈瑟氏球菌血清群A，C，W-135和Y的纯化的荚膜多糖被化学活化并通过共价化学键选择性地连接到载体蛋白上，形成能够引起对多种的长期免疫力的多糖 - 蛋白质缀合物 脑膜炎奈瑟氏球菌在儿童和成人中的应用。

公开(公告)号：US20190060475A1

公开(公告)日：2019-02-28

申请号：US16172960

申请日：2018-10-29

申请人： Sanofi Pasteur Inc.

发明人： Robert P. Ryall

IPC分类号： A61K47/64 ,  A61K47/61

摘要： The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.

公开(公告)号：US08999354B2

公开(公告)日：2015-04-07

申请号：US14257551

申请日：2014-04-21

申请人： Sanofi Pasteur Inc.

发明人： Robert P. Ryall

IPC分类号： A61K39/095 ,  A61K39/385 ,  A61K39/02 ,  A61K39/00 ,  A01N43/04 ,  C07H1/00 ,  A61K47/48 ,  A61K39/116

CPC分类号： A61K47/64 ,  A61K39/095 ,  A61K39/116 ,  A61K39/39 ,  A61K47/02 ,  A61K47/08 ,  A61K47/24 ,  A61K47/61 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70

摘要： The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.

公开(公告)号：US08734813B2

公开(公告)日：2014-05-27

申请号：US13843037

申请日：2013-03-15

申请人： Sanofi Pasteur Inc.

发明人： Robert P. Ryall

IPC分类号： A61K39/095 ,  A61K39/385 ,  A61K39/02 ,  A61K39/00 ,  A01N43/04 ,  C07H1/00

CPC分类号： A61K47/64 ,  A61K39/095 ,  A61K39/116 ,  A61K39/39 ,  A61K47/02 ,  A61K47/08 ,  A61K47/24 ,  A61K47/61 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70

摘要： The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.

摘要翻译： 本发明描述了一种联合疫苗，其提供针对脑膜炎球菌引起的脑膜炎球菌疾病的广泛保护。 疫苗由四种不同的多糖 - 蛋白质缀合物组成，其被配制成单一剂量的疫苗。 来自脑膜炎奈瑟氏球菌血清群A，C，W-135和Y的纯化的荚膜多糖被化学活化并通过共价化学键选择性地连接到载体蛋白上，形成能够引起对多种的长期免疫力的多糖 - 蛋白质缀合物 脑膜炎奈瑟氏球菌在儿童和成人中的应用。

公开(公告)号：US20160000928A1

公开(公告)日：2016-01-07

申请号：US14855994

申请日：2015-09-16

申请人： Sanofi Pasteur Inc.

发明人： Robert P. Ryall

IPC分类号： A61K47/48 ,  A61K47/02 ,  A61K47/08 ,  A61K39/095 ,  A61K39/39

CPC分类号： A61K47/64 ,  A61K39/095 ,  A61K39/116 ,  A61K39/39 ,  A61K47/02 ,  A61K47/08 ,  A61K47/24 ,  A61K47/61 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70

摘要： The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults

摘要翻译： 本发明描述了一种联合疫苗，其提供针对脑膜炎球菌引起的脑膜炎球菌疾病的广泛保护。 疫苗由四种不同的多糖 - 蛋白质缀合物组成，其被配制成单一剂量的疫苗。 来自脑膜炎奈瑟氏球菌血清群A，C，W-135和Y的纯化的荚膜多糖被化学活化并通过共价化学键选择性地连接到载体蛋白上，形成能够引起对多种的长期免疫力的多糖 - 蛋白质缀合物 脑膜炎奈瑟氏球菌在儿童和成人中的应用

公开(公告)号：US20130216571A1

公开(公告)日：2013-08-22

申请号：US13843037

申请日：2013-03-15

申请人： Sanofi Pasteur Inc.

发明人： Robert P. Ryall

IPC分类号： A61K39/095

CPC分类号： A61K47/64 ,  A61K39/095 ,  A61K39/116 ,  A61K39/39 ,  A61K47/02 ,  A61K47/08 ,  A61K47/24 ,  A61K47/61 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70

摘要： The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.

公开(公告)号：US20130177588A1

公开(公告)日：2013-07-11

申请号：US13738698

申请日：2013-01-10

申请人： SANOFI PASTEUR INC.

发明人： Robert P. Ryall

IPC分类号： A61K39/116

CPC分类号： A61K47/64 ,  A61K39/095 ,  A61K39/116 ,  A61K39/39 ,  A61K47/02 ,  A61K47/08 ,  A61K47/24 ,  A61K47/61 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70

摘要： The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.

公开(公告)号：US10143757B2

公开(公告)日：2018-12-04

申请号：US15816211

申请日：2017-11-17

申请人： Sanofi Pasteur Inc.

发明人： Robert P. Ryall

IPC分类号： A61K39/095 ,  A61K47/64 ,  A61K39/116 ,  A61K39/39 ,  A61K47/24 ,  A61K47/02 ,  A61K47/08 ,  A61K47/61 ,  A61K39/00

摘要： The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.